Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1483-1485

  Ilsar, R ^a,b   Levitt, J ^b   Ng, M K C ^a,b   Kritharides, L ^c   Adams, M R ^a,b   Celermajer, D S ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

AGED; ARTERIAL WALL THICKENING; ARTERIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART CATHETERIZATION; HEART RATE; HUMAN; INTRAVASCULAR ULTRASOUND; LETTER; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG CAPILLARY PRESSURE; LUNG ENDOTHELIUM; MALE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SCLERODERMA; SYSTOLIC BLOOD PRESSURE; TISSUE REGENERATION;

ACETYLCHOLINE; AGED; ANTIHYPERTENSIVE AGENTS; ARGININE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; PULMONARY ARTERY; SULFONAMIDES;

EID: 78649739407     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00083910     Document Type: Letter

References (10)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
2. Scott PJ, Essop AR, al-Ashab W, et al. Imaging of pulmonary vascular disease by intravascular ultrasound. Int J Card Imaging 1993; 9: 179-184.
3. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium- dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440-446.
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
5. Verma S, Lovren F, Dumont AS, et al. Endothelin receptor blockade improves endothelial function in human internal mammary arteries. Cardiovasc Res 2001; 49: 146-151.
6. Pearl JM, Wellmann SA, McNamara JL, et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 1999; 68: 1714-1721.
7. Lattimore J-DL, Wilcox I, Adams MR, et al. Treatment of obstructive sleep apnoea leads to enhanced pulmonary vascular nitric oxide release. Int J Cardiol 2008; 126: 229-233.
8. Celermajer DS, Dollery C, Burch M, et al. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 1994; 89: 2041-2044.
9. Kielstein JT, Bode-Boger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418.
10. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 2001; 358: 1119-1123. (Pubitemid 32971843)